SRI Human Sleep Lab used Oura to study how cycle-related hormonal fluctuations might impact women
Biomedical sciences
How the COVID-19 pandemic and machine learning delivered insights into adolescent mental health
An ABCD Study® paper delivers insights into the pandemic’s impact on adolescents
SRI International announces collaboration agreement with Janssen
Collaboration focuses on SRI’s Synfini artificial intelligence and automation platform to accelerate small-molecule drug discovery
Kitware leads development of Medical Image Quality Assurance (MIQA) software
SRI Bioscience awarded $14.7 million contract to continue development of high-concentration Naloxone formulation
MENLO PARK, CA (December 8, 2021)— SRI Biosciences has been awarded a $14.7 million contract sponsored by the Defense Threat Reduction Agency (DTRA) through the Medical, Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC) to continue development of a high-concentration naloxone product for intravenous, intramuscular and subcutaneous injection, or intravenous infusion. Under the three-year contract, […]
75 Years of Innovation: Bioscience
A technological quest to make the world healthier
Making Distributed Teams More Connected
HOPO: Partnering to Advance Therapy for Radiation Exposure
SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
The risk of depression in emerging adults suddenly tripled during COVID-19, and young women are particularly vulnerable
SRI’s Dr. Fiona Baker speaks on the results of a recent study on the increased risk of depression during the COVID 19 pandemic.
